AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03217058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-based screening and behavioral interventions
Description: As part of routine HIV primary care visits, patients will complete self-administered computerized substance use, anxiety and depression screening measures. Results will be integrated into the electronic health record. A behavioral health specialist on the clinic staff will contact patients who screen positive for high-risk substance use, anxiety or depression, and offer behavioral interventions including motivational interviewing and cognitive behavioral therapy.
Study NCT04221373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso™ powered exoskeleton
Description: Powered exoskeletal-assisted walking (EAW) for early training
Study NCT04221373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will receive standard of care of acute inpatient rehabilitation.
Study NCT04221373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants will receive standard of care of acute inpatient rehabilitation.
Study NCT04904952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine tablet 600mg
Description: N-acetylcysteine tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
Study NCT04904952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet 600mg
Description: Placebo tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
Study NCT01946295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 100mg x 2 p.o.
Study NCT01946295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00467051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00467051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or subcutaneously
Study NCT00467051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT00467051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT00467051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03740152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Light Therapy
Description: Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)
Study NCT04420975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Definitive Surgical Resection
Description: Undergo definitive surgical resection
Study NCT04420975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nanoplexed Poly I:C BO-112
Description: Given intratumorally
Study NCT04420975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04420975 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04425876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib combined with mFOLFIRINOX followed by maintenance Fluzoparib monotherapy
Study NCT03130634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
Study NCT03096249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
Study NCT03096249 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo spray: single dose (3 puffs per nostril).
Study NCT03626935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed customized guide plate
Description: 3D-printed customized guide plate will be used in the ankle arthrodesis to help reduce operation time and reduce intra-operative radiation.
Study NCT04066127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ischemic heart preservation (NIHP)
Description: The device is a miniaturized and fully automated heart-lung machine, housed in a portable device (weight 32 kg), that enables transportation between hospitals. The reservoir is filled with 2.5 liters of the perfusion solution plus approximately 500 mL compatible washed and leucocyte-filtered red blood cells from the hospital blood bank. The NIHP system software is adjusted to maintain a mean blood pressure of 20-25 mmHg in the aortic root, giving a coronary flow between 150 mL/min and 250 mL/min.
Study NCT04066127 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard ischemic cold static storage (SCS)
Description: The device is a cool box that enables transportation between hospitals. The heart is stored on ice slush in the box at a temperature of approximately 4-8 °C.
Study NCT01172327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise
Description: This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.
Study NCT01172327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
Study NCT02778269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12-lead ECG T-shirt
Description: The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.
Study NCT02778269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G4-System
Description: Continuous Glucose Monitoring
Study NCT01959217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PM Component Text Reminders
Description: The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text reminders will be determined by Phase 1.
Study NCT02966366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Study NCT03294811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: The telemonitoring interference in the telemonitoring arm consists of a smartphone application that helps the patient to take their medication in time and to take their blood pressure and weight on a daily basis in order to improve the medication uptitration and medication compliance.
Study NCT04520633 — intervention group
Intervention type: OTHER
Intervention: biologic initiation
Description: introduction or modification of biotherapy at M0
Study NCT02353273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WH-1 ointment
Description: Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
Study NCT01481480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Latissimus dorsi tendon transfer
Description: Latissimus dorsi tendon transfer
Study NCT01481480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic repair
Description: Arthroscopic repair
Study NCT02821572 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Study NCT02821572 — intervention group
Intervention type: PROCEDURE
Intervention: spleen sample
Study NCT03826056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current standard discharge educational intervention
Description: The patients will receive the current hospital standard discharge educational material which explains the diagnosis, new medications, follow up and any activity/diet restrictions. A member of the study team will explain this material to the patient and answer any questions.
Study NCT04281030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMR (Progressive muscle relaxation therapy)
Description: Technique for learning to monitor and control the state of muscular tension. The relaxation therapy should take about 20 minutes a day.
Study NCT04128930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP titration at home
Description: Fixed CPAP or APAP titration at home
Study NCT04128930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP titration at home
Description: Fixed CPAP or APAP titration at home
Study NCT02389179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: The drug/dosage of Vitamin D3 will be given monthly or bi-weekly depending on the type of arm that the subjects are randomised into under direct supervision.
Study NCT04281030 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitored Usual Care (MUC)
Description: Subjects will be given basic migraine information such as evidence-based ways to treat migraine: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
Study NCT04654793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted inclined bed treatment and FES
Description: FES was performed at the same time as the robot-assisted inclined bed treatment once a day for 30 minutes, 5 days a week for 4 weeks.
Study NCT04654793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional inclined bed treatment
Description: conventional inclined bed treatment for 30 minutes once a day for 4 weeks, 5 days a week
Study NCT00503698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 20 mcg/kg/day, injected s.c. (under the skin)
Study NCT00503698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo injected s.c (under the skin)
Study NCT00153179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acipimox
Description: subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit
Study NCT04055779 — intervention group
Intervention type: OTHER
Intervention: estimation method for arterial occlusion pressure
Description: The patients will receive induced hypotensive anaesthesia and the tourniquet pressure will be based on the AOP.the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=\[SBP+10\]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
Study NCT04055779 — intervention group
Intervention type: OTHER
Intervention: the limb occlusion pressure
Description: : using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
Study NCT00153179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study NCT01759602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (Cinryze)
Study NCT04842071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-sodium fluoride
Description: Intravenous injection of 4 MBq/kg for pediatric patients, or 5 MBq/kg for adult patients (maximum of 555 MBq), followed by a 45 minutes waiting time. Patients is then placed in supine position in a PET/CT scanner for a duration of no more than 30 minutes.
Study NCT01146171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-844203 (CT-322)
Description: Injection, IV, 1 and 2 mg/kg, Weekly, Until disease progression or unacceptable toxicity became apparent
Study NCT03037593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3
Description: vitamin D supplementation (4000 IU vitamin D3 +prenatal vitamin
Study NCT00127114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Study NCT00127114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00443690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofylline
Description: rolofylline 30 mg IV QD; 3 days
Study NCT00443690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: rolofylline Pbo 30 mg IV QD; 3 days
Study NCT03826056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized discharge educational intervention
Description: The patients will receive a new personalized discharge educational material which will explain the specifics of their disorder, the treatment, and prognosis. The materials will contain simple, organized explanations and graphics. A member of the study team will explain this material to the patient and answer any questions.
Study NCT04974021 — intervention group
Intervention type: DRUG
Intervention: Ferric carboxymaltose
Description: Intravenous ferric carboxymaltose for the treatment of iron deficiency in HFrEF as per 2016 European Society of Cardiology Heart Failure guidelines.
Study NCT01299324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BMAC infusion
Description: Infusion of 60 mL of Bone Marrow Aspirate Concentrate
Study NCT02052206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder replacement surgery
Study NCT01569321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT01569321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-CT scan
Study NCT01569321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEM scan with ClearPemSonic
Study NCT01695681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gluten-free diet
Description: Dietary advice by clinical dietitian
Study NCT03280472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification
Description: CBM training. For those in the CBM condition, participants will complete a task. In this task, they will read ambiguous, two- to four-sentence social-related scenarios on the computer. The final word in the scenario will have a missing letter. Participants will type the missing letter. Participants will also be asked to answer a Yes/No comprehension question about the scenario. The missing letter will resolve the ambiguity of the scenario in a positive way, intended to train participants to have more positively-biased interpretations of ambiguous social information
Study NCT03280472 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Symptom tracking
Description: Participants will track their symptoms
Study NCT02726997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02726997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT02726997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02726997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02726997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02726997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02628197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium (500mg) and vitamin D (250I.U.)
Description: calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months
Study NCT02628197 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
Study NCT04038411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Antibody, chidamide, lenalidomide and etoposide
Description: PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
Study NCT03405545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intenstiy interval training
Description: High-intensity interval training is a training of 30 minutes involving 10 bouts of 1 minute high intensity cycling (80-90% of maximum heart rate) interspersed by 2 minutes rest.
Study NCT00066573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: Given orally
Study NCT00066573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given orally
Study NCT03049592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIBISCUS counseling
Description: Third trimester prenatal appointment with a family planning specialist for contraceptive counseling utilizing the Contraceptive CHOICE counseling script - emphasizing the WHO birth-to-pregnancy recommendation of 18 months, and a follow up postpartum contraception visit with a family planning specialist.
Study NCT01680757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LARIAT Suture Delivery Device and Accessories
Study NCT04125082 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Afrezza Inhalant Product
Description: Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
Study NCT03022526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSE
Study NCT03022526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Study NCT03022526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine / fentaNYL
Study NCT03022526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine / fentaNYL
Study NCT01229865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-111
Study NCT03785782 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Breast ultrasound
Study NCT04005599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil group
Description: Venous general anesthesia with propofol and remifentanil.
Study NCT04005599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate group
Description: Venous general anesthesia with propofol and magnesium sulfate
Study NCT03430934 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NAVI mapping with Indocyanine green
Description: Moh's tumor imaging with Indocyanine green
Study NCT04459377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ketamine
Description: Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed.